Novabay Therapeutics (NBY)

NovaBay is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing proprietary anti-infective, auriclosene (formerly NVC-422), with a novel mechanism of action, and the potential not to elicit drug resistance from microbe – a phenomena frequently seen in traditional antibiotics and antifungal agents.  Auriclosene is being tested clinically in multiple clinical trials in various areas such as urology (in urinary catheter blockage and encrustation or UCBE), dermatology (for impetigo in collaboration with Galderma S.A.), and ophthalmology (in viral conjunctivitis). In addition, the company is in collaboration ex-U.S. partners to commercialize its FDA approved NeutroPhase in chronic non-healing wound therapy management.  Pioneer Pharma is the current leading partner with reach on the China and Southeast Asian markets.  As several major in-development programs are maturing with material events to come over the next 12 months, the company also is heading into a period with multiple potential catalysts starting in 2014 and beyond.